Trial · NCT01386658
Results by group144
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 144
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Peak Concentration (Tmax) of a Single Subcutaneous (SC) Dose of Icatibant | Prepubertal | 0.42 | Standard Deviation 0.13 | Hour (h) | |
| Time to Peak Concentration (Tmax) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: With Acute Attack | 0.55 | Standard Deviation 0.19 | Hour (h) | |
| Time to Peak Concentration (Tmax) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: Without Acute Attack | 0.57 | Standard Deviation 0.17 | Hour (h) | |
| Maximum Plasma Concentration (Cmax) of a Single Subcutaneous (SC) Dose of Icatibant | Prepubertal | 659 | Standard Deviation 158 | Nanogram per milliliter (ng/mL) | |
| Maximum Plasma Concentration (Cmax) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: With Acute Attack | 805 | Standard Deviation 125 | Nanogram per milliliter (ng/mL) | |
| Maximum Plasma Concentration (Cmax) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: Without Acute Attack | 761 | Standard Deviation 133 | Nanogram per milliliter (ng/mL) | |
| Total Plasma Clearance (CL/F) of a Single Subcutaneous (SC) Dose of Icatibant | Prepubertal | 10.8 | Standard Deviation 4.63 | Milliliters per minute (mL/min) | |
| Total Plasma Clearance (CL/F) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: With Acute Attack | 13.1 | Standard Deviation 3.42 | Milliliters per minute (mL/min) | |
| Total Plasma Clearance (CL/F) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: Without Acute Attack | 19.3 | Standard Deviation 4.84 | Milliliters per minute (mL/min) | |
| Area Under the Plasma Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4) of a Single Subcutaneous (SC) Dose of Icatibant | Prepubertal | 1241 | Standard Deviation 319 | Hour*nanogram per milliliter (h*ng/mL) | |
| Area Under the Plasma Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: With Acute Attack | 1448 | Standard Deviation 304 | Hour*nanogram per milliliter (h*ng/mL) | |
| Area Under the Plasma Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: Without Acute Attack | 1335 | Standard Deviation 211 | Hour*nanogram per milliliter (h*ng/mL) | |
| Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours Post-dose (AUC0-t) of a Single Subcutaneous (SC) Dose of Icatibant | Prepubertal | 1289 | Standard Deviation 325 | h*ng/mL | |
| Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours Post-dose (AUC0-t) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: With Acute Attack | 1573 | Standard Deviation 372 | h*ng/mL | |
| Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours Post-dose (AUC0-t) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: Without Acute Attack | 1398 | Standard Deviation 225 | h*ng/mL | |
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of a Single Subcutaneous (SC) Dose of Icatibant | Prepubertal | 1243 | Standard Deviation 244 | h*ng/mL | |
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: With Acute Attack | 1710 | Standard Deviation 569 | h*ng/mL | |
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: Without Acute Attack | 1416 | Standard Deviation 229 | h*ng/mL | |
| Volume of Distribution (Vz/F) of a Single Subcutaneous (SC) Dose of Icatibant | Prepubertal | 12.5 | Standard Deviation 5.28 | Liters (L) | |
| Volume of Distribution (Vz/F) of a Single Subcutaneous (SC) Dose of Icatibant | Pubertal/Postpubertal: With Acute Attack | 23.5 | Standard Deviation 13.9 | Liters (L) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01386658/results